New Commitments. Neither Party will incur new expenses related to this CRADA after expiration, mutual termination, or a notice of a unilateral termination and will, to the extent feasible, cancel all outstanding commitments and contracts by the termination date. Collaborator acknowledges that ICD will have the authority to retain and expend any funds for up to one (1) year subsequent to the expiration or termination date to cover any unpaid costs obligated during the term of the CRADA in undertaking the research and development activities set forth in the Research Plan.
Appears in 18 contracts
Samples: Cooperative Research and Development Agreement (Bavarian Nordic a/S / ADR), Material Transfer Agreement (Newlink Genetics Corp), And Development Agreement (Intercept Pharmaceuticals Inc)
New Commitments. Neither Party will incur new expenses related to this CRADA after expiration, mutual termination, or a notice of a unilateral termination and will, to the extent feasible, cancel all outstanding commitments and contracts by the termination date. Collaborator acknowledges that ICD IC will have the authority to retain and expend any funds for up to one (1) year subsequent to the expiration or termination date to cover any unpaid costs obligated during the term of the CRADA in undertaking the research and development activities set forth in the Research Plan.
Appears in 13 contracts
Samples: Research and Development Agreement, Research and Development Agreement, Cooperative Research and Development Agreement (Scopus BioPharma Inc.)
New Commitments. Neither Party will incur new expenses related to this CRADA after expiration, mutual termination, or a notice of a unilateral termination and will, to the extent feasible, cancel all outstanding commitments and contracts by the termination date. Collaborator acknowledges that ICD will have the authority to retain and expend any funds for up to one (1) year […***…] subsequent to the expiration or termination date to cover any unpaid costs obligated during the term of the CRADA in undertaking the research and development activities set forth in the Research Plan.
Appears in 6 contracts
Samples: Agreement (Tracon Pharmaceuticals, Inc.), Research and Development Agreement (Tracon Pharmaceuticals Inc), Research and Development Agreement (Kite Pharma, Inc.)
New Commitments. Neither Party will incur new expenses related to this CRADA after expiration, mutual termination, or a notice of a unilateral termination and will, to the extent feasible, cancel all outstanding commitments and contracts by the termination date. Collaborator acknowledges that ICD CDC will have the authority to retain and expend any funds for up to one (1) year subsequent to the expiration or termination date to cover any unpaid costs obligated during the term of the CRADA in undertaking the research and development activities set forth in the Research Plan.
Appears in 4 contracts
Samples: Public Health Service, Public Health Service, Public Health Service
New Commitments. Neither Party will incur new expenses related to this CRADA after expiration, mutual termination, termination or a notice of a unilateral termination and will, to the extent feasible, cancel all outstanding commitments and contracts by the termination date. Collaborator acknowledges that ICD IC will have the authority to retain and expend any funds for up to one five (15) year years subsequent to the expiration or termination date to cover any unpaid costs obligated during the term of the CRADA in undertaking the research and development activities set forth in the Research Plan.
Appears in 2 contracts
Samples: Public Health Service, Cooperative Research and Development Agreement
New Commitments. Neither Party will incur new expenses related to this CRADA after expiration, mutual termination, termination or a notice of a unilateral termination and will, to the extent feasible, cancel all outstanding commitments and contracts by the termination date. Collaborator acknowledges that ICD IC will have the authority to retain and expend any funds for up to one (1) year […***…] years subsequent to the expiration or termination date to cover any unpaid costs obligated during the term of the CRADA in undertaking the research and development activities set forth in the Research Plan.
Appears in 2 contracts
Samples: Agreement (Tracon Pharmaceuticals, Inc.), Agreement (Tracon Pharmaceuticals Inc)
New Commitments. Neither Party will incur new expenses related to this CRADA after expiration, mutual termination, termination or a notice of a unilateral termination and will, to the extent feasible, cancel all outstanding commitments and contracts by the termination date. Collaborator acknowledges that ICD NCI will have the authority to retain and expend any funds for up to one five (15) year years subsequent to the expiration or termination date to cover any unpaid costs obligated during the term of the CRADA in undertaking the research and development activities set forth in the Research Plan.
Appears in 1 contract
Samples: Health Service
New Commitments. Neither Party will incur new expenses related to this CRADA after expiration, mutual termination, or a notice of a unilateral termination termination, and each Party will, to the extent feasible, cancel all outstanding commitments and contracts by the termination date. Collaborator acknowledges that ICD IC will have the authority to retain and expend any funds provided by the Collaborator during the term of this CRADA (if any) for up to one (1) year [*] subsequent to the expiration or termination date to cover any unpaid costs obligated during the term of the CRADA in undertaking the research and development activities set forth in the Research Plan.
Appears in 1 contract
Samples: Material Transfer Agreement (Newlink Genetics Corp)
New Commitments. Neither Party will incur new expenses related to this CRADA after expiration, or mutual termination, or a notice of a unilateral termination and will, to the extent feasible, cancel all outstanding commitments and contracts by the termination date. Collaborator acknowledges that ICD IC will have the authority to retain and expend any funds previously paid by Collaborator for up to one two and one-half (12.5) year years subsequent to the expiration or termination date to cover any unpaid costs obligated during the term of the CRADA in undertaking the research and development activities set forth in the Research Plan.
Appears in 1 contract
New Commitments. Neither Party will incur new expenses related to this CRADA after expiration, mutual termination, or a notice of a unilateral termination and will, to the extent feasible, cancel all outstanding commitments and contracts by the termination date. Collaborator acknowledges that ICD FDA will have the authority to retain and expend any funds for up to one (1) year subsequent to the expiration or termination date to cover any unpaid costs obligated during the term of the CRADA in undertaking the research and development activities set forth in the Research PlanPIan.
Appears in 1 contract
New Commitments. Neither Party will incur new expenses related to this CRADA after expiration, mutual termination, or a notice of a unilateral termination and will, to the extent feasible, cancel all outstanding commitments and contracts by the termination date. Collaborator acknowledges that ICD will have the authority to retain and expend any funds for up to one (1) year [*] subsequent to the expiration or termination date to cover any unpaid costs obligated during the term of the CRADA in undertaking the research and development activities set forth in the Research Plan.
Appears in 1 contract
New Commitments. Neither Party will incur new expenses related to this CRADA after expiration, mutual termination, or a notice of a unilateral termination and will, to the extent feasible, cancel all outstanding commitments and contracts by the termination date. Collaborator acknowledges that ICD IC will have the authority to retain and expend any funds for up to one (1) year subsequent to the expiration or termination date to cover any unpaid costs obligated during the term of the CRADA in undertaking the research and development activities set forth in the Research Plan.. PHS CRADA Agreement Ref. No. 2020-12 MODEL ADOPTED June 18, 2009
Appears in 1 contract
Samples: Development Agreement (Virpax Pharmaceuticals, Inc.)
New Commitments. Neither Party will incur new expenses related to this CRADA after expiration, mutual termination, termination or a notice of a unilateral termination and will, to the extent feasible, cancel all outstanding commitments and contracts by the termination date. Collaborator acknowledges that ICD NCI will have the authority to retain and expend any necessary funds for up to one five (15) year years subsequent to the expiration or termination date to cover any unpaid unpaid, undisputed costs obligated during the term of the CRADA in undertaking the research and development activities set forth in the Research PlanPlan in accordance with this CRADA.
Appears in 1 contract
Samples: Public Health Service